Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Unknown 2Terminated 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Non-Small-Cell Lung 42Lung Neoplasms 18Melanoma 14Carcinoma, Hepatocellular 14Neoplasm Metastasis 13Esophageal Neoplasms 11Squamous Cell Carcinoma of Head and Neck 9Breast Neoplasms 8Head and Neck Neoplasms 6Esophageal Squamous Cell Carcinoma 6Rectal Neoplasms 5Colorectal Neoplasms 5Stomach Neoplasms 4Recurrence 4Neoplasms 4Carcinoma, Renal Cell 4Brain Neoplasms 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Multiple Myeloma 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Radiation Pneumonitis 2Pathologic Complete Response 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Oropharyngeal Neoplasms 2

Interventions

Gemcitabine 83Cisplatin 53Oxaliplatin 36lenvatinib 25Capecitabine 23durvalumab 22Fluorouracil 20Leucovorin 15tislelizumab 11pembrolizumab 11apatinib 10Radiotherapy 10Albumin-Bound Paclitaxel 10Radiofrequency Ablation 9Magnetic Resonance Spectroscopy 9Irinotecan 9Floxuridine 9Liver Transplantation 8Drug Therapy 8Cholangiopancreatography, Endoscopic Retrograde 8130-nm albumin-bound paclitaxel 8Taxes 7S 1 (combination) 7Platinum 7Photochemotherapy 7Panitumumab 7Biopsy 71,2-diaminocyclohexaneplatinum II citrate 7tremelimumab 6pemigatinib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Cholangiocarcinoma × Immunotherapy × Clear all
NCT04989218 2024-11-05

ICC

University of Alabama at Birmingham

Phase 1/2 Terminated
1 enrolled 11 charts
Gastrointestinal

Cholangiocarcinoma

NCT04333927 2020-06-23

ACCORD

Sun Yat-sen University

Phase 2 Unknown
92 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04413734 2020-06-04

Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma

Zhejiang University

Phase 2 Unknown
120 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡